Story

Insulet Stock Extends Decline on Lingering Guidance Concerns

ENTHMSVIIDZHZH-TWJAKOHI
Sep 28, 20261 min read
Insulet Stock Extends Decline on Lingering Guidance Concerns

Summary

Shares of Insulet Corp. (PODD) fell more than 2% as investors continue to react to a previous cut in full-year revenue guidance, analyst price target reductions, and a broader market downturn.

Text size
Background

Shares of Insulet Corp. (NASDAQ: PODD) extended a prolonged decline in mid-day trading on September 28, 2026, falling to a price near their 52-week low. The slide reflects persistent investor concern following a downward revision to the company's full-year revenue guidance in August, compounded by subsequent analyst downgrades and a broader market sell-off.

Post-Earnings Fallout

The stock's weakness traces back to its second-quarter 2026 earnings report. While Insulet delivered results that surpassed analyst estimates for revenue and profit, the company simultaneously lowered its full-year revenue outlook. Management attributed the guidance cut to softer-than-expected patient retention among its Type 2 diabetes users in the U.S., a development that rattled investor confidence in a key growth narrative.

This has led to a sustained de-rating of the stock. In response to the revised outlook, Wall Street analysts have progressively reduced their price targets on Insulet shares. The consensus target has been reset to approximately $144, reflecting more cautious assumptions about the company's future growth, profit margins, and valuation.

Sample IUX Markets – In-articleAd

Market and Company Headwinds

The sell-off was exacerbated by a negative session for the broader market. The S&P 500 declined 0.6% and the Nasdaq Composite fell 0.7%, creating a risk-off environment that often puts additional pressure on high-multiple growth stocks in the healthcare sector.

Other contributing factors include recent leadership changes. Two long-serving board directors stepped down in early September 2026, creating what the source described as "governance noise" for the company. Insulet's stock fell 2.3% to $132.96, just above its 52-week low of $126.40 and in stark contrast to its 52-week high of $354.88.

Read next

More on Stocks
TotalEnergies, Equinor Tipped for Strong Q3 Earnings by TD Cowen

Stocks

TotalEnergies, Equinor Tipped for Strong Q3 Earnings by TD Cowen

Sep 28, 2026

TD Cowen analysts have highlighted their top integrated oil picks ahead of earnings season, citing a rising commodity environment that consensus estimates have yet to fully capture. The firm expects the sector to generate $100 billion in excess cash through late 2027.

Back to latest news

LATEST